South Africa Hospital Delivers HDR Brachytherapy Cancer Treatments with Varian Bravos Afterloader System
PALO ALTO, Calif. and CAPE TOWN, South Africa, April 30, 2019 -- (Healthcare Sales &Marketing Network) -- Varian (NYSE: VAR) announced Groote Schuur Hospital in Cape Town, South Africa is the first hospital in Africa to deliver High Dose Rate (HDR) brach... Devices, Oncology Varian Medical Systems, Bravos afterloader, HDR brachytherapy, radiotherapy
The aim of this review was to examine efficacy of palliative interventional radiotherapy (IRT) in esophageal cancer compared with other treatment in terms of dysphagia-free survival (DyFS) and safety.
CONCLUSIONS: Penile cancer needs demanding surgery to be cured, surrounded by chemotherapy in node positive patients. Lymph nodes involvement is a major prognostic factor. Thus, inguinal node assessment cannot be neglected. PMID: 31610869 [PubMed - in process]
High dose-rate (HDR) brachytherapy for recurrent prostate cancer post-radiotherapy is an accepted salvage method. This prospective non-controlled clinical study investigates HDR-like stereotactic body radiotherapy (SBRT) as a less invasive alternative and evaluates efficacy and toxicity in patients with biopsy proven local recurrence. This method appears clinically feasible, with favorable PSA response, disease control to 5 years in the majority of patients, and acceptably low GU and GI toxicity.
Radical cystectomy (RC) is still considered standard of treatment for patients with non-metastatic muscle-invasive bladder cancer (MIBC) and high-risk non-muscle-invasive bladder cancer (NMIBC) refractory to intravesical therapy in most countries . However, RC has significant morbidity and mortality .
To compare a standard radio-oncological and a surgical biochemical failure definition after combined-modality radiation therapy (CRT) in men with intermediate- and high-risk prostate cancer.
Condition: Cervical Cancer Intervention: Sponsor: Peking University Third Hospital Recruiting
In conclusion, the addition of triapine to cisplatin-radiotherapy improved the rate of metabolic complete response in patients with advanced-stage uterine cervix or vaginal cancers without significant toxicity. A phase III trial adequately powered to evaluate progression-free and overall survival is underway (NCT02466971).
The objective function considers pairs of dose points and each pair is given a distance-based penalty if the dose is either too high or too low at both dose points. Constraints are included to retain dosimetric indices at acceptable levels. Our model is designed to automate the manual adjustment step in the planning process. In the automatic adjustment step large-scale optimization models are solved. We show reductions of the volumes of the largest hot and cold spots, and the computing times are feasible in clinical practice. PMID: 31610533 [PubMed - as supplied by publisher]
We report here oncological outcomes and toxicity of hypofractionated breast irradiation. After defining the frame of moderate and extreme hypofractionated breast irradiations based on overall treatment time, patient selection criteria were listed. According to their levels of proof, the results of moderate and extreme hypofractionated breast irradiation were analysed. Overall treatment time for moderate hypofractionated breast irradiation ranged from 3 to 4 weeks, while for extreme hypofractionated breast irradiation, it was less than 1 week. For moderate hypofractionated breast irradiation, whole breast irradiation w...
Whole pelvis radiotherapy (WPRT) may improve clinical outcomes over prostate-only radiotherapy (PORT)in high-risk prostate cancer patients by sterilization of micrometastatic nodal disease provided there is optimal control of the primary site.